NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has increased by 41.8% and is now trading at $15.05.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Accelerate Diagnostics.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Accelerate Diagnostics Inc (NASDAQ:AXDX) released its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.39) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.39). The medical research company had revenue of $2.34 million for the quarter, compared to the consensus estimate of $2.40 million. Accelerate Diagnostics had a negative net margin of 845.43% and a negative return on equity of 5,681.44%.
View Accelerate Diagnostics' earnings history.

3 brokerages have issued twelve-month price objectives for Accelerate Diagnostics' stock. Their forecasts range from $14.00 to $19.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics.

News articles about AXDX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Accelerate Diagnostics.

Accelerate Diagnostics saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 15,760,000 shares, a decrease of 8.9% from the June 30th total of 17,300,000 shares. Based on an average daily volume of 497,200 shares, the days-to-cover ratio is currently 31.7 days. Currently, 56.3% of the company's shares are sold short.
View Accelerate Diagnostics' Current Options Chain.

Some companies that are related to Accelerate Diagnostics include Horiba (HRIBF), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), BioNano Genomics (BNGO), Precipio (PRPO), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC) and PositiveID (PSID).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Chicago Capital LLC (1.37%), UBS Group AG (0.15%) and SG Americas Securities LLC (0.03%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Romney Humphries, Steven Reichling and Thomas D Brown.
View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, and UBS Group AG.
View insider buying and selling activity for Accelerate Diagnostics.

AXDX stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown.
View insider buying and selling activity for Accelerate Diagnostics.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXDX stock can currently be purchased for approximately $15.05.

Accelerate Diagnostics has a market capitalization of $831.83 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]